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MICROABSTRACT 
This open-label, non-randomized study examined the safety and tolerability of combination 
pertuzumab, subcutaneous trastuzumab (Herceptin®) and taxane chemotherapy in previously 
untreated patients with HER2-positive metastatic breast cancer.  Fifty patients were assessed.  
Overall response rate was 73.3% (95% CI: 58.1-85.4%), median progression free survival was 
17.0 months (95% CI: 12.5--31.2 months). This combination has acceptable safety and 
tolerability profile. 
ABSTRACT 
Purpose: The primary objective was to assess the safety and tolerability of combination 
pertuzumab, subcutaneous trastuzumab (Herceptin®) and investigator’s choice taxane 
chemotherapy in previously untreated HER2-positive metastatic breast cancer (mBC) patients.  
Efficacy was a secondary objective. 
Methods: An open-label, non-randomized study of HER2-positive mBC patients who had no 
previous systemic non-hormonal anti-cancer therapy for metastatic disease.  Primary endpoints 
included adverse events (AE), serious adverse events and cardiac adverse events.  Secondary 
endpoints included overall response rate (ORR), progression free survival (PFS) and overall 
survival (OS).  Patients were treated with pertuzumab and subcutaneous trastuzumab in three-
weekly cycles with taxane chemotherapy until disease progression, unacceptable toxicity or 
withdrawal of consent and followed for a minimum of 24-months from initiation of study 
treatment. 
Results: Fifty patients were enrolled and included in the analysis.  All patients experienced at 
least one AE, with diarrhea, fatigue, peripheral neuropathy, alopecia, rash and nausea the most 
common.  Three patients experienced at least one grade 3 event of suspected cardiac origin 
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(cardiac failure, cardiomyopathy, hypertension).  Six patients withdrew from therapy due to AEs 
(cardiac failure, drug hypersensitivity, decreased left ventricular ejection fraction, syncope and 
bullous dermatitis).  Taxane chemotherapy comprised nab-paclitaxel (74.0% of patients), 
docetaxel (28.0%) or paclitaxel (4.0%).  ORR was 73.3% (95% CI: 58.1-85.4%), median PFS 
was 17.0 months (95% CI: 12.5-31.2 months) and median OS was not reached. 
Conclusions: Subcutaneous trastuzumab in this combination has an acceptable safety and 
tolerability profile, including cardiac safety profile.  Safety and efficacy appear similar to 
previous studies of intravenous trastuzumab in this combination.   
Trial registration: ClinicalTrials.gov, NCT02019277. Registered 24 December 2013, 
https://clinicaltrials.gov/ct2/show/NCT02019277 
 
Keywords: Pertuzumab; subcutaneous trastuzumab; breast cancer; human epidermal growth 
factor receptor 2 (HER2), metastases 
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LIST OF ABBREVIATIONS 
CI: confidence interval; CR: complete response; CTC: Common Terminology Criteria; ECG: 
electrocardiogram; ECOG: Eastern Cooperative Oncology Group; HER2: human epidermal 
growth factor receptor 2; IHC: immunohistochemistry; ITT: intent-to-treat; IV: intravenous; 
LVEF: left ventricular ejection fraction; mBC: metastatic breast cancer; NCI CTCAE: National 
Cancer Institute Common Terminology Criteria for Adverse Events; NYHA: New York Heart 
Association; ORR: overall response rate; OS: overall survival; PFS: progression free survival; 
PR: partial response; SC: subcutaneous; SD: stable disease. 
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BACKGROUND 
In approximately 15% to 20% of primary breast cancers, human epidermal growth factor receptor 
2 (HER2) is either amplified or overexpressed (HER2-positive).1  HER2-positive tumors have 
more aggressive biology. Treatment of HER2-positive breast cancer with anti-HER2 targeted 
therapy is standard of care for both early and metastatic breast cancer (mBC). Intravenous (IV) 
trastuzumab has proven clinical benefits in patients with HER2-positive mBC.  Pertuzumab also 
targets HER2 through an independent epitope to that of trastuzumab and inhibits dimerization 
with other HER family members, particularly HER3.2  . The pivotal CLEOPATRA study in 
HER2-positive mBC demonstrated acceptable toxicity and improved efficacy for pertuzumab IV 
in combination with  trastuzumab IV and docetaxel compared to placebo, trastuzumab IV and 
docetaxel.3  The median PFS was 12.4 months (95% CI 10.4 to 13.5 months) in the placebo 
group and 18.7 months (16.6 to 21.6 months) in the pertuzumab group.  Overall survival (OS) 
was 40.8 months (95% CI 35.8 to 48.3 months) in the placebo group and 56.5 months (95% CI 
49.3 to not estimable) in the pertuzumab group (hazard ratio 0.68, 95% CI 0.56 to 0.84; P<0.001) 
after a median follow-up of 50 months in both groups.  There was no increase in left ventricular 
systolic dysfunction but the rates of grade 3 or worse febrile neutropenia and diarrhea were 
higher in the pertuzumab group. 
Based on the results of the CLEOPATRA study, pertuzumab gained regulatory approval for use 
in Australia in combination with trastuzumab and docetaxel, but not with other taxanes. 
Pertuzumab was later funded for use in combination with trastuzumab and either docetaxel or 
paclitaxel.  The subcutaneous formulation of trastuzumab (trastuzumab SC) had not been 
approved in Australia at the time this study was conducted, although the intravenous formulation 
was already standard of care.  The safety and efficacy of other chemotherapy partners with 
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pertuzumab IV and trastuzumab IV are now reported, notably for vinorelbine (the VELVET 
study)4, and for nab-paclitaxel and paclitaxel (the PERUSE study),5 the latter in abstract alone. 
The SAPPHIRE study was the first study to investigate the combination of trastuzumab SC with 
pertuzumab IV and taxane chemotherapy.  Trastuzumab SC has the potential to reduce infusion 
chair time and so be more convenient for patients.  It has been shown to have a pharmacokinetic 
profile and efficacy that is non-inferior to the intravenous formulation and with a similar safety 
profile.6, 7  Patients have reported a preference for subcutaneous over intravenous 
administration.8, 9 
The primary objective of this study was to assess the safety and tolerability of the combination of 
pertuzumab, trastuzumab SC and taxane chemotherapy of the investigator’s choice (docetaxel, 
paclitaxel or nab-paclitaxel) in patients with previously untreated HER2-positive mBC.  
Exploratory safety analyses by type of taxane chemotherapy administered were also conducted.  
The secondary objectives of this study were to assess the efficacy of the pertuzumab IV, 
trastuzumab SC and taxane chemotherapy combination. 
PATIENTS AND METHODS 
Trial design 
This open-label, multicenter, phase IIIb study of first line treatment for HER2-positive mBC 
(NCT02019277) was conducted according to Good Clinical Practice guidelines and the 
Declaration of Helsinki.  All patients provided written informed consent.  The independent ethics 
committee for each participating center approved the protocol and amendments. 
The primary endpoints were safety endpoints including adverse events, serious adverse events 
and cardiac adverse events.  Secondary endpoints included overall response rate (ORR; either 
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confirmed complete response (CR) or partial response (PR) as determined by RECIST criteria, 
Version 1.1), PFS and OS.  PFS was defined as the time from the visit prior to treatment start 
until the first documented disease progression or death, whichever came first.  Patients who had 
neither progressed nor died or who were lost to follow-up at the time of the analysis were 
censored at the date of their last tumor assessment where non-progression was documented or the 
last date of follow-up, whichever was later.  OS was defined as the time from baseline until death 
from any cause.  Patients still alive at the time of the analysis or lost to follow-up were censored 
at their last clinical assessment date. 
Patient population 
Eligible patients were adults with HER2-positive, histologically or cytologically confirmed 
adenocarcinoma of the breast with metastatic disease with at least one measurable lesion and/or 
non-measurable disease according to RECIST Version 1.1.  Patients were required to have 
immunohistochemistry 3+ (IHC3+) or in-situ hybridization positive (ISH+) HER2-positive 
disease of the primary tumor or metastatic site.  Patients who received docetaxel were required to 
have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or 0, 1 or 2 
for paclitaxel or nab-paclitaxel.  Baseline left ventricular ejection fraction (LVEF) was required 
to be at least 50%.  Previous use of either adjuvant or neoadjuvant anti-HER2 therapy was 
allowed.  Hormonal therapy was allowed as per institutional guidelines but not in combination 
with taxane therapy. 
Patients were ineligible to participate if they had received previous non-hormonal anti-cancer 
therapy for the treatment of mBC; were pregnant or breastfeeding; had current peripheral 
neuropathy grade 3-5 (National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) Version 4.0); had radiographic evidence of central nervous system 
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metastases except where treated, stable for at least 3 months and ongoing corticosteroid treatment 
was not required; had concurrent serious diseases that may have interfered with planned 
treatment, including severe pulmonary conditions/illnesses.  . 
 
Study treatment 
Pertuzumab (F. Hoffmann-La Roche Ltd) was administered every three weeks as an IV infusion; 
loading dose ( 840 mg) was given on Day 1 of the first 21-day treatment cycle, followed by 420 
mg on Day 1 of each subsequent 21-day cycle, irrespective of body weight.  Fixed dose 
trastuzumab SC (Herceptin®, F. Hoffmann-La Roche Ltd; 600 mg/5 mL) was administered on 
Day 2 of the first treatment cycle, then once every three weeks.  If both drugs were well tolerated 
during the first treatment cycle, trastuzumab SC could be administered after pertuzumab IV on 
Day 1 of subsequent treatment cycles, followed by taxane chemotherapy.  Commercially 
available docetaxel, paclitaxel or nab-paclitaxel, as chosen by the investigator, were administered 
following the local product information for each drug and as per routine clinical practices .  
Doses of taxane chemotherapy were calculated according to the patient’s body surface area using 
actual body weight; dosing schedule was in accordance with the local Product Information.   
Patients with unacceptable toxicity or disease progression were switched to standard treatment of 
the investigator’s choice.  If pertuzumab and trastuzumab SC were withheld for two cycles 
because of unacceptable toxicity, the patient was withdrawn from both study treatments.  Taxane 
chemotherapy could be continued as first-line study treatment until disease progression.  If taxane 
chemotherapy was permanently discontinued due to unacceptable toxicity, pertuzumab and 
trastuzumab SC administration continued as first-line study treatment until disease progression. 
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Assessments 
Routine tumor assessments (RECIST Version 1.1) were performed by the investigator every nine 
weeks from time of first dose of trastuzumab and pertuzumab until disease progression or death.  
Electrocardiograms (ECGs) and assessments of left ventricular ejection fraction (LVEF) were 
performed every 12 weeks from time of first dose of trastuzumab and pertuzumab and at the 
safety follow-up visit.  Laboratory tests were performed every cycle and at the safety follow-up 
visit.  ECOG performance status was assessed every three cycles and at the safety follow-up visit.  
Patients were followed for a minimum of 24 months from initiation of study treatment.  Survival 
status information was collected every three months. 
Adverse events were reported throughout the treatment period and up to 28 days following last 
dose of trastuzumab and pertuzumab.  All adverse events considered related to study treatment, 
and all cardiac adverse events regardless of causality assessment, were required to be reported 
until study closure. 
Statistical considerations 
No formal hypothesis testing was planned.  The planned sample size of 50 patients was based on 
an acceptable level of precision for the incidence of adverse events considered related to 
trastuzumab or pertuzumab of NCI CTCAE grade 3 or worse.  For 50 patients, an incidence of 
10% would provide a 95% Clopper-Pearson confidence interval (CI) of 3.3% to 21.8%, and an 
incidence of 50%, would provide a 95% CI of 35.5% to 64.5%. 
All primary analyses were performed on the safety population including all enrolled patients who 
received at least one dose of pertuzumab or trastuzumab.  All baseline summaries and efficacy 
analyses were based on the intent-to-treat (ITT) population including all enrolled patients 
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scheduled to receive pertuzumab and trastuzumab.  The taxane chemotherapy subgroup 
(docetaxel, paclitaxel or nab-paclitaxel) was defined at the time of enrolment.  Patients who 
switched chemotherapy were assigned to the taxane group in which they had most cycles, or if 
equally administered, to their initial taxane group.  Comparisons by taxane chemotherapy group 
are considered post-hoc analyses. 
Endpoints related to adverse events, serious adverse events, cardiac events and administration-
associated reactions were summarized by number and percentage of patients having any event 
and 95% Clopper-Pearson CI. 
Secondary efficacy endpoints included ORR, PFS and OS. ORR was assessed by the number and 
proportion of responders and non-responders, together with two-sided 95% CIs.  Only patients 
with measurable disease at baseline (enrolment) were included in the analysis.  Patients without a 
post-baseline assessment were considered non-responders.  The analysis of PFS and OS was 
based on the survivor function, which is the probability of remaining event-free beyond a certain 
point in time.  The survival function was estimated using the Kaplan-Meier method and 
summarized using the range, the 25th and 75th percentiles, the median and a 95% CI for the 
median. 
RESULTS 
Study population 
Fifty patients were enrolled in the study between December 2013 and October 2014 at 12 
hospitals across Australia (see Figure 1).  The data cut-off date was 21 March 2017. 
Selected patient baseline characteristics are presented in Table 1.  No patients had brain 
metastases at baseline. 
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Treatment exposure 
Patients received a median of 19.0 cycles (min to max: 1 to 49 cycles) of trastuzumab and 
pertuzumab.  Exposure to taxane chemotherapy was much lower with a median of 6.0 cycles (1 
to 15 cycles).  Nab-paclitaxel was received for 7.0 cycles (1 to 11 cycles), docetaxel for 6.0 
cycles (1 to 15 cycles) and paclitaxel for 2.5 cycles (1 to 4 cycles). 
Thirty-seven patients (74.0%) received nab-paclitaxel during the study, 14 patients (28.0%) 
received docetaxel and two patients (4.0%) received paclitaxel.  Three patients switched taxane 
chemotherapy: one patient received nab-paclitaxel for two cycles then switched to paclitaxel for 
one cycle (included in nab-paclitaxel group); one patient received docetaxel for one cycle then 
switched to nab-paclitaxel for 14 cycles (nab-paclitaxel group); one patient received docetaxel for 
one cycle then switched to nab-paclitaxel for one cycle (docetaxel group). 
Thirty-six patients discontinued study treatment: 6 patients (12.0%) due to adverse events and 20 
patients (40.0%) due to progressive disease (Figure 1).  Fourteen patients (28.0%) did not 
progress and switched to commercial stock of trastuzumab and pertuzumab at the completion of 
the study; no further data were collected from this point. 
Thirty-one (62.0%) patients had hormone receptor positive breast cancer; 15 patients received at 
least one hormonal therapy during the study of whom 14 received hormonal therapy after 
stopping study taxanes.  
Primary Safety Endpoints 
All patients experienced at least one adverse event during the study, with diarrhea, fatigue, 
peripheral neuropathy, alopecia, rash and nausea the most common events (Table 2).  There were 
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349 adverse events in the docetaxel group (27 events per patient), 707 in the nab-paclitaxel group 
(20 events per patient) and 6 in the paclitaxel group (6 events per patient). 
CTC grade 3 or 4 adverse events were experienced by 32 patients (64.0%) (Table 3).  Serious 
adverse events were experienced by 27 patients (54.0%) (Table 4).  Notably no patients in the 
nab-paclitaxel group experienced febrile neutropenia of CTC grade 3 or worse, or a serious 
adverse event of febrile neutropenia.  In addition, only one patient (2.0%), who received 
docetaxel, required concomitant granulocyte colony stimulating factors (filgrastim).  Nine 
patients (18.0%) died due to disease progression.  No deaths were considered related to study 
treatments. 
Six patients (12.0%) experienced a total of 12 adverse events of suspected cardiac origin of 
whom four patients (8.0%) experienced eight adverse events considered by the investigator to be 
related to trastuzumab, pertuzumab or both.  Three patients (6.0%) experienced five CTC grade 3 
events of suspected cardiac origin: one patient experienced cardiac failure and hypertension (both 
New York Heart Association (NYHA) Class II), one patient experienced cardiac failure and 
cardiomyopathy (both NYHA Class II) and one patient experienced cardiomyopathy (NYHA 
Class III).  Of these five events, three remained unresolved at study completion (hypertension and 
cardiac failure in one patient and cardiomyopathy in one patient).  The remaining two events, in 
one patient, resolved: one with sequelae (cardiomyopathy) and one without (cardiac failure).  
There were no grade 4 or 5 events of suspected cardiac origin. 
Forty-one patients had a decrease in LVEF from baseline.  The maximum decrease from baseline 
was less than 10% for 24 patients, and greater than 25% for one patient.  There were four (8.0%) 
patients with a decrease in LVEF below 50% at any time during the study. 
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Six patients (12.0%) experienced a total of eight administration-associated reactions, including 
one CTC grade 3 event of drug hypersensitivity reaction considered related to pertuzumab 
administration. 
Subcutaneous injection of trastuzumab was associated with only a small number of injection site 
reactions.  Twelve of 1140 injections (0.01%) were associated with pain (3 events), erythema (2 
events) or unspecified injection site reaction (7 events).  There was no obvious link between 
injection site reactions and speed of injection. 
Adverse events that led to withdrawal of trastuzumab and pertuzumab treatment were cardiac 
failure (two patients), drug hypersensitivity, decreased ejection fraction, syncope and bullous 
dermatitis (each one patient).  Ten patients (20.0%) experienced an adverse event that led to 
withdrawal of taxane chemotherapy.  Eight of 36 patients (22.2%) who received nab-paclitaxel 
and two of 13 patients (15.4%) who received docetaxel discontinued chemotherapy due to 
adverse events.  No patients discontinued paclitaxel due to adverse events; however, only two 
patients received paclitaxel chemotherapy at any time during the study.  Overall, the most 
common adverse events leading to chemotherapy withdrawal were diarrhea and peripheral 
neuropathy. 
Secondary efficacy endpoints 
Forty-five patients had measurable disease at baseline.  Thirty-three patients had a partial or 
complete response to study treatment giving an ORR of 73.3% (95% CI 58.1% to 85.4%).  Eight 
patients had stable disease (SD; 17.8% (95% CI 8.0% to 32.1%)) and three patients had 
progressive disease (6.7% (95% CI 1.4% to 18.3%).  One patient was not evaluated. 
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The clinical benefit rate,10, 11 which considers CR, PR and SD, was 91.1% (95% CI 78.8% to 
97.5%).  In this study, clinical benefit was defined as CR, PR and SD occurring at any time 
during treatment. 
Thirty patients (60.0%) had a PFS event with a median PFS of 17.0 months (95% CI 12.5 to 31.2 
months) (Figure 2A).  Nine patients (18.0%) died during the study.  Median OS was not reached 
during the study treatment period (95% CI: 31.3 months to not calculable) (Figure 2B). 
Twenty-three patients started second-line therapy, the most commonly used therapies being 
trastuzumab (13 patients), trastuzumab emtansine (10 patients), capecitabine (8 patients), 
pertuzumab (5 patients), lapatinib (4 patients) and paclitaxel (4 patients).  Second line median OS 
from failure of first-line therapy until death from any cause was 21.3 months (95% CI: 14.9 to 
29.0 months) (Figure 2C). 
The median (min to max) length of time on the study was 18.8 months (0.76 to 34.5 months). 
DISCUSSION 
The observed safety profile combination trastuzumab SC and pertuzumab IV is similar to that in 
the CLEOPATRA study 3 suggesting that the subcutaneous trastuzumab formulation in this 
combination has a comparable safety and tolerability profile.  There were two notable differences 
in this study compared with the CLEOPATRA study: an apparent higher frequency of peripheral 
neuropathy and lower frequency of neutropenia.  These differences are considered to be 
associated with the common use of nab-paclitaxel in this study, as opposed to docetaxel, which 
all patients received in the CLEOPATRA study.  In the PERUSE study 5 of intravenous 
trastuzumab and pertuzumab and taxane of the investigator’s choice, a lower frequency of 
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neutropenia and higher frequency of peripheral neuropathy considered related to the use of 
paclitaxel and nab-paclitaxel, was also observed. 
Nab-paclitaxel appears to be a valid alternative chemotherapy to docetaxel in combination with 
trastuzumab SC and pertuzumab IV, and was commonly chosen by Australian oncologists over 
docetaxel and paclitaxel in this study.There were no cases of neutropenic fever in the nab-
paclitaxel group. 
As in the CLEOPATRA study, a low incidence of cardiac adverse events and decreased LVEF 
was observed in this study.  In this study 12.0% of patients experienced any event of suspected 
cardiac origin and 6.0% experienced at least one CTC grade 3 event of suspected cardiac origin, 
compared with cardiac adverse events experienced by 16.4% of patients in the placebo treatment 
group (3.8% CTC grade 3 or above), and 14.5% of patients in the pertuzumab treatment group 
(1.5% grade 3 or above) in CLEOPATRA.12  Only four patients (8.0%) had a decrease in LVEF 
below 50% at any time during this study and in CLEOPATRA 4.4% of patients receiving 
pertuzumab and 6.6% of patients receiving placebo had a LVEF decrease of ≥ 10% below 50%.12 
Median OS was not reached in this study, consistent with the long OS observed in the 
CLEOPATRA study,3 despite a higher percentage of patients in the SAPPHIRE study having 
received previous HER2 targeted therapy in the adjuvant setting.  PFS was also similar to that 
observed in the CLEOPATRA study. 
The clinical benefit rate of the combination in this study was over 90%.  All patients in the study 
were fit enough at the end of the study to go onto another treatment, suggesting that the 
progression of disease on treatment was not rapid. 
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The SAPPHIRE study had less restrictive eligibility criteria than the CLEOPATRA study.  Only 
10% of patients in the CLEOPATRA study had had adjuvant trastuzumab compared with 30% in 
SAPPHIRE. 
The ongoing MetaPHER study (NCT02402712) is a single arm phase IIIB study which aims to 
evaluate safety and efficacy of trastuzumab SC, pertuzumab IV and docetaxel IV in first line 
HER2+ locally advanced or mBC.  Data from the second interim analysis of 418 patients has 
been reported at ESMO 2018 and the interim safety and efficacy profiles appear consistent with 
the known safety profile of trastuzumab IV and pertuzumab IV. Final results are awaited.13  
Limitations of the SAPPHIRE study include small sample size, non-randomised design with lack 
of comparator arm, and insufficient follow-up to determine OS.  Comparisons of adverse events 
by type of taxane chemotherapy were performed as post-hoc analyses.  However, the study 
should be generalizable to standard clinical practice, with a representative sample of older and 
younger breast cancer patients and patients with comorbid conditions including cardiovascular 
conditions such as atrial fibrillation. 
Conclusion 
SAPPHIRE is the first study to report on the combination of trastuzumab SC, pertuzumab IV and 
taxane of investigators choice. Nab-paclitaxel was the most common physician choice and was 
observed to be an acceptable alternative to docetaxel with the combination.  SAPPHIRE suggests 
that trastuzumab SC in this combination has an acceptable safety and tolerability profile, 
including cardiac safety profile, with efficacy appearing similar to previous studies of 
trastuzumab IV in the combination. 
Clinical practice points 
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• Improved efficacy (both progression free survival and overall survival) with acceptable 
toxicity has been shown in metastatic breast cancer using intravenous pertuzumab in 
combination with intravenous trastuzumab and docetaxel.  
• SAPPHIRE an open-label, multicenter, phase IIIb study was the first study to investigate 
`the combination of intravenous pertuzumab, subcutaneous trastuzumab and clinician’s 
choice taxane chemotherapy in previously untreated patients with HER2-positive 
metastatic breast cancer.  The study showed that this combination had acceptable safety 
and tolerability profile. 
• Nab-paclitaxel appears to be a valid alternative chemotherapy to docetaxel in combination 
with trastuzumab SC and pertuzumab IV, and was commonly chosen over docetaxel and 
paclitaxel in this study.   
• Notwithstanding the small sample size, of clinical interest is the low overall incidence of 
decreased left ventricular ejection fraction in the study and the absence of grade 3+ febrile 
neutropenia in the nab-paclitaxel group. 
• The clinical benefit rate of the combination in this study was over 90%.  All patients in 
the study were fit enough at the end of the study to go onto another treatment, suggesting 
that the progression of disease on treatment was not rapid. 
 
 
ACKNOWLEDGMENTS 
We thank all patients and investigators participating in this trial.  The principal investigators were 
Dr Jacqui Adams, Dr Maree Colosimo, Dr Katharine Cuff, Dr Jeremy Power, Dr Mustafa 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 22
Khasra, Dr Janine M Lombard, Dr Daphne Tsoi, Dr Jodi Lynch and Dr Stephen Begbie.  We also 
thank the Roche study team. 
J. Steyne, of Novotech (Australia) Pty Limited, performed statistical analyses funded by Roche 
Products Pty Limited. 
Sophie Gibb, PhD CMPP, of WriteSource Medical Pty Limited provided medical writing 
support, funded by Roche Products Pty Limited in accordance with Good Publication Practice 
(GPP3) guidelines (http://www.ismpp.org/gpp3). 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 23
 
REFERENCES 
1. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for Human Epidermal 
Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical 
Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal 
of Clinical Oncology. 2013;31:3997-4013. 
2. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights 
into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 
2004;5:317-328. 
3. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-
positive metastatic breast cancer. N Engl J Med. 2015;372:724-734. 
4. Perez EA, Lopez-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in 
combination with pertuzumab and trastuzumab for first-line treatment of patients with 
HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final 
results. Breast Cancer Res. 2016;18:126. 
5. Miles D, Puglisi F, Schneeweiss A, et al. 1816 Preliminary safety results from PERUSE, 
a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with 
trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast 
cancer (LR/mBC). European Journal of Cancer. 2015;51:S271. 
6. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration 
of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast 
cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet 
Oncol. 2012;13:869-878. 
7. Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation 
of trastuzumab for HER2-positive early breast cancer: updated results from the phase III 
HannaH study. Ann Oncol. 2015;26:320-325. 
8. Pivot X, Spano JP, Espie M, et al. Patients' preference of trastuzumab administration 
(subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of 
the randomised MetaspHer study. Eur J Cancer. 2017;82:230-236. 
9. Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intravenous 
administration of trastuzumab in patients with HER2-positive early breast cancer 
(PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962-970. 
10. Amiri-Kordestani L, Cheng J, Zhang L, et al. Association of clinical benefit rate (CBR) 
with survival: A pooled-analysis of metastatic breast cancer (MBC) trials submitted to the 
US Food and Drug Administration (FDA): American Society of Clinical Oncology; 2016. 
11. Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what 
matters most? A review of clinical endpoints in advanced breast cancer. The Oncologist. 
2011;16:25-35. 
12. Swain SM, Ewer MS, Cortes J, et al. Cardiac tolerability of pertuzumab plus trastuzumab 
plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: 
a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18:257-
264. 
13. Kümmel S, Tondini CA, Abraham J, et al. 323PSubcutaneous trastuzumab (H SC) with 
intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 24
cancer (BC): MetaPHER second interim analysis. Annals of Oncology. 
2018;29:mdy272.313-mdy272.313. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 25
Tables 
Table 1: Demographics and baseline characteristics 
Parameter  
Age, years (SD) 52.9 (12.0) 
Sex, n (%)  
Female 49 (98.0) 
Male  1 (2.0) 
BMI, mean (SD) 27.9 (6.4) 
Race, n (%)  
White 42 (84.0) 
Asian 4 (8.0) 
Other 4 (8.0) 
Female reproductive status [N=49], n (%)  
Childbearing 15 (30.6) 
Surgically Sterile 4 (8.2) 
Post-Menopausal 30 (61.2) 
ECOG PS, n (%)  
0 33 (66.0) 
1 15 (30.0) 
2 2 (4.0) 
Disease presentation at screening, n (%)  
De novo 23 (46.0) 
Relapse 27 (54.0) 
HER2 status at screening, n (%)  
HER2+ 50 (100) 
ISH+ 44 (88) 
IHC3+ (ISH not tested)   6 (12) 
Hormone receptor status, n (%)  
ER+ or PR+ or both 31 (62.0) 
ER- and PR- 19 (38.0) 
Prior hormonal therapy in hormone positive patients, 
n (%) 
20 (40.0) 
Any anti-estrogen 15 (30.0) 
Aromatase inhibitors 12 (24.0) 
Gonadotropin and analogues 3 (6.0) 
Conjugated estrogens and medroxyprogesterone 1 (2.0) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 26
Prior chemotherapy/trastuzumab in adjuvant setting, 
n (%) 
23 (46.0) 
Anthracyclines 17 (34.0) 
Taxanes 17 (34.0) 
Trastuzumab 15 (30.0) 
Median time from last trastuzumab dose in eBC 
[n=15], months (min, max) 
22.1 (0.5, 62.3) 
eBC early breast cancer 
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Table 2: Any grade adverse events occurring in > 7 patients (15%) in the total patient population 
AE preferred term Docetaxel 
n = 13 
Nab-Paclitaxel 
n = 36 
Paclitaxel 
n =1 
Total 
N = 50 
Diarrhea 9 (69.2) 27 (75.0) - 36 (72.0) 
Fatigue 8 (61.5) 26 (72.2) - 34 (68.0) 
Peripheral neuropathy 3 (23.1) 24 (66.7) 1 (100.0) 28 (56.0) 
Alopecia 7 (53.8) 20 (55.6) - 27 (54.0) 
Rash 7 (53.8) 18 (50.0) 1 (100.0) 26 (52.0) 
Nausea 4 (30.8) 18 (50.0) 1 (100.0) 23 (46.0) 
Upper respiratory tract infection 7 (53.8) 12 (33.3) - 19 (38.0) 
Myalgia 4 (30.8) 14 (38.9) - 18 (36.0) 
Headache 5 (38.5) 12 (33.3) - 17 (34.0) 
Vomiting 4 (30.8) 13 (36.1) - 17 (34.0) 
Muscle spasms 5 (38.5)   9 (25.0) - 14 (28.0) 
Arthralgia 5 (38.5)   6 (16.7) 1 (100.0) 12 (24.0) 
Epistaxis 3 (23.1)   9 (25.0) - 12 (24.0) 
Gastroesophageal reflux disease 6 (46.2)   6 (16.7) - 12 (24.0) 
Nail disorder 4 (30.8)   8 (22.2) - 12 (24.0) 
Pain in extremity 4 (30.8)   7 (19.4) - 11 (22.0) 
Urinary tract infection 3 (23.1)   8 (22.2) - 11 (22.0) 
Back pain 2 (15.4)   8 (22.2) - 10 (20.0) 
Constipation 3 (23.1)   6 (16.7) -    9 (18.0) 
Cough 2 (15.4)   7 (19.4) -    9 (18.0) 
Dizziness 3 (23.1)   6 (16.7) -    9 (18.0) 
Pyrexia 2 (15.4)   7 (19.4) -    9 (18.0) 
Neutropenia 5 (38.5)   3   (8.3) -    8 (16.0) 
Dry skin 4 (30.8)   4 (11.1)     8 (16.0) 
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Table 3: Grade 3+ adverse events in more than 1 patient (2%) in the total patient population 
AE preferred term Docetaxel 
n = 13 
Nab-Paclitaxel 
n = 36 
Paclitaxel 
n =1 
Total 
N = 50 
Neutropenia 3 (23.1) 3 (8.3) - 6 (12.0) 
Febrile neutropenia 4 (30.8) - - 4   (8.0) 
Diarrhea 1 (7.7) 2 (5.6) - 3    (6.0) 
Peripheral neuropathy 1 (7.7) 2 (5.6) - 3   (6.0) 
Anaemia - 2 (5.6) - 2    (4.0) 
Cardiac failure - 2 (5.6) - 2   (4.0) 
Cardiomyopathy - 2 (5.6) - 2   (4.0) 
Cellulitis - 2 (5.6) - 2   (4.0) 
Dyspnea 1 (7.7) 1 (2.8) - 2   (4.0) 
Pulmonary Embolism - 2 (5.6) - 2   (4.0) 
Pyrexia 1 (7.7) 1 (2.8) - 2   (4.0) 
Upper respiratory tract infection 1 (7.7) 1 (2.8)  2   (4.0) 
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Table 4: Serious adverse events occurring in more than 1 patient (2%) in the total patient 
population 
SAE preferred term 
Docetaxel 
n = 13 
Nab-Paclitaxel 
n = 36 
Paclitaxel 
n =1 
Total 
N = 50 
Pyrexia 2 (15.4) 5 (13.9) - 7 (14.0) 
Febrile neutropenia 4 (30.8) - - 4   (8.0) 
Cellulitis - 2   (5.6) 
 
2   (4.0) 
Pulmonary embolism - 2   (5.6) - 2   (4.0) 
Upper respiratory tract infection 1 (7.7) 2   (5.6)  2   (4.0) 
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Figure Legends 
Figure 1: Patient flow through the study 
Figure 2: Kaplan-Meier curve of a) PFS (ITT population), b) OS (ITT population) and c) OS 
(second-line therapy; ITT population) 
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Assessed for eligibility
n=53
Enrolled
n=50
Excluded
n=3*
Excl. criterion 2 -
history of malignancy (n=1)
Excl. criterion 8 - inadequate 
organ function (n=3)
* one patient was excluded for 
both criteria
Discontinued study treatment
n=50
Adverse event/intercurrent illness (n=6)
Progression of disease (n=20)
Violation of selection criteria at entry (n=1)
Refused treatment / did not cooperate (n=7)
Withdrew consent (n=2)
Completion of study (n=14)
Discontinued safety follow-up 
n=4
Adverse event/intercurrent illness (n=1)
Did not cooperate (n=1)
Withdrew consent (n=2)
Discontinued survival follow-up 
n=8
Death (n=7)
Withdrew consent (n=1)
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